Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asana BioSciences, a US-based research and development firm specializing in the discovery and development of new chemical and biological entities, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International.
Subscribe to our email newsletter
Portfolio of Asana includes multiple compounds for oncology and pain indications that are ready to enter clinical trials.
Asana chief executive officer Sandeep Gupta said the company’s mission is to develop new and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients.
"Our team consists of highly experienced scientists who have successfully executed several drug discovery and clinical development projects," Gupta said.
"I am very excited about this portfolio and am looking forward to initiating our First-in-Man trials for our lead asset and moving other assets into clinical development."
Until recently, Gupta served as the senior vice president of Discovery and Early Development at Endo Pharmaceuticals.
Amneal Pharmaceuticals co-CEO and co-chairman Chintu Patel said, "I’m pleased to announce the launch of Asana BioSciences, which expands the Amneal Alliance of Companies’ footprint in pharmaceutical drug discovery, in addition to its generic, specialty and biologics capabilities."
The Amneal Alliance of Companies is an alliance of independent companies which focus on various disciplines within the life sciences.